Guardant nets Medicare coverage for solid tumor test

2017 09 14 23 05 1167 Cancer Cell 400

Guardant Health's Guardant360 TissueNext test has received Medicare coverage under an existing local coverage determination by Medicare administrative contractor Palmetto GBA.

The new policy covers Guardant360 TissueNext as a standalone service for Medicare fee-for-service patients with advanced solid-tumor cancers. Guardant360 TissueNext -- the firm's first tissue-based test -- can assist oncologists in identifying cancer patients who may benefit from biomarker-informed treatment, Guardant said.

Page 1 of 193
Next Page